Anxiety
Articles about Anxiety
U.S. FDA Grants Reunion Neuroscience’s Luvesilocin (RE104) Breakthrough Therapy Designation Status
-- Breakthrough Therapy Designation Based on Positive RECONNECT Phase 2 Clinical Data --
As More Americans Embrace Anxiety Treatment, MAHA Derides Medications
Robert F. Kennedy Jr. has criticized the broadening use of anxiety medications, claiming they’re harmful. Doctors and researchers say the MAHA movement is misrepresenting drugs that have been proved to safely treat chronic anxiety and point to broader social changes to explain their increased use.
As more Americans embrace anxiety treatment, RFK Jr. derides medications
Robert F. Kennedy Jr. has criticized the broadening use of anxiety medications, but doctors and researchers say the MAHA movement is misrepresenting drugs that have been proven to help.
Contact The Gross Law Firm By March 16, 2026 Deadline To Join Class Action Against Vistagen Therapeutics, Inc.(VTGN)
(MENAFN - GlobeNewsWire - Nasdaq) NEW YORK, Feb. 18, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Vistagen Therapeutics, Inc. (NASDAQ: VTGN). ...
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Vistagen Therapeutics, Inc. Investors to Secure ...
NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) --
Lenire Shows Consistent Positive Results For U.S. Tinnitus Patients In 2Nd Peer-Reviewed Real-World Study
(MENAFN - PR Newswire) 81.8% of patients with bothersome tinnitus treated with Lenire at New York Hearing Doctors reported significant improvement in a real-world clinical setting.1,2 Patients ...
VTGN SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Reminds Vistagen Therapeutics (VTGN) Investors ...
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered In Vistagen To Contact Him Directly To Discuss Their Options
VTGN Investors with Large Losses Should Contact Robbins LLP for Information About Leading the ...
SAN DIEGO, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a class action was filed on behalf of all investors who purchased or otherwise acquired Vistagen Therapeutics, Inc. (NASDAQ: VTGN) common stock between April 1, 2024 and...
‘Longevity fixation syndrome’: the allure of eternal youth
Obsession with beating biological clock identified as damaging new addiction
Vistagen Reports Fiscal Year 2026 Third Quarter Financial Results and Provides Corporate Update
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Feb 12, 2026--
Vanda Pharmaceuticals Q4 Earnings Call Highlights
Vanda Pharmaceuticals (NASDAQ:VNDA) highlighted strong growth for its lead product Fanapt and detailed several late-stage regulatory and clinical milestones during its fourth-quarter and full-year 2025 earnings call, while also reporting a sharply wider net loss driven largely by a one-time, non-cash tax charge. Fanapt growth offset by Hetlioz pressure from generics Chief Executive Officer Dr. [...]
What is EMDR therapy, and who can it help?
EMDR therapy is best known for helping people recover from trauma, but it may also benefit those with anxiety, depression, and other mental health conditions.